270 related articles for article (PubMed ID: 16832131)
21. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial.
Regine WF; Winter KA; Abrams RA; Safran H; Hoffman JP; Konski A; Benson AB; Macdonald JS; Kudrimoti MR; Fromm ML; Haddock MG; Schaefer P; Willett CG; Rich TA
JAMA; 2008 Mar; 299(9):1019-26. PubMed ID: 18319412
[TBL] [Abstract][Full Text] [Related]
22. What options are available for refractory pancreatic cancer?
Choi M; Kim R; Saif MW
JOP; 2012 Mar; 13(2):163-5. PubMed ID: 22406591
[TBL] [Abstract][Full Text] [Related]
23. TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial).
Ioka T; Ueno M; Ueno H; Park JO; Chang HM; Sasahira N; Kanai M; Chung IJ; Ikeda M; Nakamori S; Mizuno N; Omuro Y; Yamaguchi T; Hara H; Sugimori K; Furuse J; Maguchi H; Furukawa M; Fukuzawa K; Kim JS; Yukisawa S; Takeuchi M; Okusaka T; Boku N; Hyodo I
Eur J Cancer; 2019 Jan; 106():78-88. PubMed ID: 30471651
[TBL] [Abstract][Full Text] [Related]
24. Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group.
Ettrich TJ; Berger AW; Perkhofer L; Daum S; König A; Dickhut A; Wittel U; Wille K; Geissler M; Algül H; Gallmeier E; Atzpodien J; Kornmann M; Muche R; Prasnikar N; Tannapfel A; Reinacher-Schick A; Uhl W; Seufferlein T
BMC Cancer; 2018 Dec; 18(1):1298. PubMed ID: 30594153
[TBL] [Abstract][Full Text] [Related]
25. Gemcitabine-induced hepatitis in a pancreatic cancer patient receiving adjuvant therapy following metastasectomy.
Saadati H; Peccerillo J; Kaley K; Schilsky ML; Saif MW
JOP; 2009 Sep; 10(5):573-5. PubMed ID: 19734642
[No Abstract] [Full Text] [Related]
26. New developments in the treatment of pancreatic cancer. Highlights from the "44th ASCO Annual Meeting". Chicago, IL, USA. May 30 - June 3, 2008.
Saif MW
JOP; 2008 Jul; 9(4):391-7. PubMed ID: 18648128
[TBL] [Abstract][Full Text] [Related]
27. Second-line therapy in gemcitabine-pretreated patients with advanced pancreatic cancer.
Boeck S; Heinemann V
J Clin Oncol; 2008 Mar; 26(7):1178-9; author reply 1179. PubMed ID: 18309957
[No Abstract] [Full Text] [Related]
28. Postoperative adjuvant gemcitabine and concurrent radiation after curative resection of pancreatic head carcinoma: a phase II study.
Van Laethem JL; Demols A; Gay F; Closon MT; Collette M; Polus M; Houbiers G; Gastelblum P; Gelin M; Houtte PV; Closset J
Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):974-80. PubMed ID: 12829132
[TBL] [Abstract][Full Text] [Related]
29. An Updated Meta-analysis and System Review:is Gemcitabine+Fluoropyrimidine in Combination a Better Therapy Versus Gemcitabine Alone for Advanced and Unresectable Pancreatic Cancer?
Tu C; Zheng F; Wang JY; Li YY; Qian KQ
Asian Pac J Cancer Prev; 2015; 16(14):5681-6. PubMed ID: 26320435
[TBL] [Abstract][Full Text] [Related]
30. Systemic therapy of advanced pancreatic cancer: has the landscape changed?
Choi M; Razzaque S; Kim R
Clin Adv Hematol Oncol; 2012 Jul; 10(7):442-51. PubMed ID: 22895284
[TBL] [Abstract][Full Text] [Related]
31. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer.
Heinemann V; Quietzsch D; Gieseler F; Gonnermann M; Schönekäs H; Rost A; Neuhaus H; Haag C; Clemens M; Heinrich B; Vehling-Kaiser U; Fuchs M; Fleckenstein D; Gesierich W; Uthgenannt D; Einsele H; Holstege A; Hinke A; Schalhorn A; Wilkowski R
J Clin Oncol; 2006 Aug; 24(24):3946-52. PubMed ID: 16921047
[TBL] [Abstract][Full Text] [Related]
32. Congestive heart failure secondary to gemcitabine nab-paclitaxel in patients with pancreatic cancer.
John P; Butler H; Saif MW
Anticancer Res; 2014 Dec; 34(12):7267-70. PubMed ID: 25503159
[TBL] [Abstract][Full Text] [Related]
33. Gemcitabine and ISIS-2503 for patients with locally advanced or metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II trial.
Alberts SR; Schroeder M; Erlichman C; Steen PD; Foster NR; Moore DF; Rowland KM; Nair S; Tschetter LK; Fitch TR
J Clin Oncol; 2004 Dec; 22(24):4944-50. PubMed ID: 15611509
[TBL] [Abstract][Full Text] [Related]
34. Options for the treatment of gemcitabine-resistant advanced pancreatic cancer.
Gounaris I; Zaki K; Corrie P
JOP; 2010 Mar; 11(2):113-23. PubMed ID: 20208317
[TBL] [Abstract][Full Text] [Related]
35. Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study.
Tsavaris N; Kosmas C; Skopelitis H; Gouveris P; Kopterides P; Loukeris D; Sigala F; Zorbala-Sypsa A; Felekouras E; Papalambros E
Invest New Drugs; 2005 Aug; 23(4):369-75. PubMed ID: 16012797
[TBL] [Abstract][Full Text] [Related]
36. Updates on treatment of gemcitabine-refractory pancreatic adenocarcinoma. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011.
Makrilia N; Syrigos KN; Saif MW
JOP; 2011 Jul; 12(4):351-4. PubMed ID: 21737894
[TBL] [Abstract][Full Text] [Related]
37. Successful adjuvant bi-weekly gemcitabine chemotherapy for pancreatic cancer without impairing patients' quality of life.
Toyama Y; Yoshida S; Saito R; Kitamura H; Okui N; Miyake R; Ito R; Son K; Usuba T; Nojiri T; Yanaga K
World J Surg Oncol; 2013 Jan; 11():3. PubMed ID: 23302293
[TBL] [Abstract][Full Text] [Related]
38. [Locally advanced unresectable pancreatic cancer: Induction chemoradiotherapy followed by maintenance gemcitabine versus gemcitabine alone: Definitive results of the 2000-2001 FFCD/SFRO phase III trial].
Barhoumi M; Mornex F; Bonnetain F; Rougier P; Mariette C; Bouché O; Bosset JF; Aparicio T; Mineur L; Azzedine A; Hammel P; Butel J; Stremsdoerfer N; Maingon P; Bedenne L; Chauffert B
Cancer Radiother; 2011 Jun; 15(3):182-91. PubMed ID: 21315644
[TBL] [Abstract][Full Text] [Related]
39. Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison with other regimens.
Wainberg ZA; Feeney K; Lee MA; Muñoz A; Gracián AC; Lonardi S; Ryoo BY; Hung A; Lin Y; Bendell J; Hecht JR
BMC Cancer; 2020 Jul; 20(1):633. PubMed ID: 32641104
[TBL] [Abstract][Full Text] [Related]
40. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale.
Colucci G; Giuliani F; Gebbia V; Biglietto M; Rabitti P; Uomo G; Cigolari S; Testa A; Maiello E; Lopez M
Cancer; 2002 Feb; 94(4):902-10. PubMed ID: 11920457
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
